Bepranemab – Talk Bio

Actionable Insights Powered by AI

Roche Abandons Tau Antibody Project, Returns Rights to UCB After $120M Investment

6 months ago talkbio0Tagged Alzheimer 's disease, Antibodies, Bepranemab, Investments, Roche (company), UCB, uridine triacetate

Roche, UCB, tau antibody, Alzheimer’s disease, bepranemab, $120M investment